|
hepatocellular carcinoma |
11 |
|
survival |
8 |
|
liver transplant |
7 |
|
recurrence |
7 |
|
systemic therapy |
7 |
|
renal palliative care |
6 |
|
biomarker |
5 |
|
cabozantinib |
5 |
|
checkpoint inhibitors |
5 |
|
combination therapy |
5 |
|
depression |
5 |
|
hospitalization |
5 |
|
targeted therapy |
5 |
|
tyrosine kinase inhibitors |
5 |
|
anthracycline |
4 |
|
breast cancer |
4 |
|
cera |
4 |
|
esa |
4 |
|
fatigue |
4 |
|
immune checkpoint inhibitors |
4 |
|
ipilimumab |
4 |
|
neoadjuvant therapy |
4 |
|
nivolumab |
4 |
|
pathologic complete response |
4 |
|
renal anemia |
4 |
|
sorafenib |
4 |
|
taxane |
4 |
|
tec |
4 |
|
anxiety |
3 |
|
caregiver burden |
3 |
|
chronic kidney failure |
3 |
|
conservative management |
3 |
|
enhanced psychosocial support |
3 |
|
hospital anxiety and depression scale (hads) |
3 |
|
palliative care |
3 |
|
quality of life (qol) |
3 |
|
randomized controlled trial (rct) |
3 |
|
social support |
3 |
|
social worker |
3 |
|
advance care planning |
2 |
|
advanced haematological malignancies |
2 |
|
cancers |
2 |
|
clinic |
2 |
|
early palliative care (early pc) |
2 |
|
early pc |
2 |
|
emergency department visit |
2 |
|
haematology palliative care |
2 |
|
healthcare cost |
2 |
|
hypothyroidism |
2 |
|
immunotherapy |
2 |
|
neoplasms |
2 |
|
palliative care follow-up |
2 |
|
quality improvement |
2 |
|
quality of life |
2 |
|
randomized controlled trials (rct) |
2 |
|
supportive care |
2 |
|
symptom burden |
2 |
|
symptom management |
2 |
|
thyroid diseases |
2 |
|
young patients |
2 |
|
aml |
1 |
|
dying |
1 |
|
elderly |
1 |
|
end-of-life |
1 |
|
hematology |
1 |
|
hospice |
1 |
|
intensive |
1 |
|
leukemia |
1 |
|
oncology |
1 |
|
palliative |
1 |
